%0 Journal Article %A Camille M. Masselot %A Bastian Greshake Tzovaras %A Chris L.B. Graham %A Gary Finnegan %A Rathin Jeyaram %A Isabelle Vitali %A Thomas E. Landrain %A Marc Santolini %T Co-Immune: a case study on open innovation for vaccination hesitancy and access %D 2021 %R 10.1101/2021.03.29.20248781 %J medRxiv %P 2021.03.29.20248781 %X Background The rise of major complex public health problems, such as vaccination hesitancy and access to vaccination, requires innovative, open and transdisciplinary approaches. In spite of this, institutional silos, paywalls and lack of participation of non-academic citizens in the design of solutions hamper efforts to meet these challenges. Against this background, new solutions have been explored, with participatory research, citizen science, hackathon and challenge-based approaches being applied in the context of public health.Objectives Our ambition was to develop a framework for creating citizen science and open innovation projects that address the contemporary challenges of vaccination in France and around the globe.Methods We designed and implemented Co-Immune, a programme created to tackle the question of vaccination hesitancy and access to vaccination through an online and offline challenge-based open innovation approach. The programme was run on the open science platform Just One Giant Lab.Results Over a 6-month period, the Co-Immune programme gathered 234 participants of diverse backgrounds and 13 partners from the public and private sectors and organized 8 events to facilitate the creation of 20 new projects as well as the continuation of 2 existing projects to address the issues of vaccination hesitancy and access, ranging from app development and data mining to analysis and game design. In an open framework, the projects made their data, code, and solutions publicly available.Conclusion Co-Immune highlights how open innovation approaches and online platforms can help to gather and coordinate non-institutional communities in a rapid, distributed and global way towards solving public health issues. Through the ideas of hackathons and other contest approaches, such initiatives can lead to the production and transfer of knowledge, creating novel solutions in the public health sector. The example of Co-Immune contributes to paving the way for organisations and individuals to collaboratively tackle future global challenges.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form. No support from any organisation during the elaboration and submission work of this manuscript; Just One Giant Lab received funding from Sanofi to develop and implement the programme which include publication fees. Sanofi respected the strict independence of JOGL, which administers its platform and the Co-Immune page in complete autonomy. Similarly, the Committee for Ethics, Science and Impact (CESI) was independent of Sanofi and decided alone on the strategic and scientific orientations of the program and the best projects to be rewarded. GF was paid by Just One Giant Lab to support the elaboration of the manuscript; provided consulting services to Vaccines Europe, a trade association based in Belgium and is a volunteer board member of the Coalition for Life-Course Immunisation, a UK-based charity ; no other relationships or activities that could appear to have influenced the submitted work.Funding StatementJust One Giant Lab received funding from Sanofi to develop and implement the programme which include publication fees.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Commission Nationale de l'Informatique et des Libertes registration number 2221728 (Methodologie de reference MR-004).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available in open access on Zenedo under the Licence: Creative Commons Attribution 4.0 International. https://doi.org/10.5281/zenodo.4560273 %U https://www.medrxiv.org/content/medrxiv/early/2021/04/07/2021.03.29.20248781.full.pdf